Adalimumab ameliorates memory impairments and neuroinflammation in chronic cerebral hypoperfusion rats

Vascular dementia (VaD) is the second most common type of dementia worldwide. Although there are five FDA-approved drugs for the treatment of Alzheimer’s disease (AD), none of them have been applied to treat VaD. Adalimumab is a TNF-α inhibitor that is used for the treatment of autoimmune diseases s...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jing-Jing, Guo, Si, Xue, Rui, Xiao, Lin, Kou, Jun-Na, Liu, Yu-Qiong, Han, Jun-Ya, Fu, Jing-Jie, Wei, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202885/
https://www.ncbi.nlm.nih.gov/pubmed/34030135
http://dx.doi.org/10.18632/aging.203009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202885/
https://www.ncbi.nlm.nih.gov/pubmed/34030135
http://dx.doi.org/10.18632/aging.203009

Ejemplares similares